| Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult J Jacobi, GL Fraser, DB Coursin, RR Riker, D Fontaine, ET Wittbrodt, ... Critical care medicine 30 (1), 119-141, 2002 | 2472 | 2002 |
| Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ... Journal of the American College of Cardiology 71 (23), 2628-2639, 2018 | 470 | 2018 |
| Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study HJL Heerspink, A Karasik, M Thuresson, C Melzer-Cohen, G Chodick, ... The lancet Diabetes & endocrinology 8 (1), 27-35, 2020 | 288 | 2020 |
| Low-dose oral naloxone reverses opioid-induced constipation and analgesia M Liu, E Wittbrodt Journal of pain and symptom management 23 (1), 48-53, 2002 | 253 | 2002 |
| Drugs and myasthenia gravis: an update ET Wittbrodt Archives of internal medicine 157 (4), 399-408, 1997 | 160 | 1997 |
| SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL MA Cavender, A Norhammar, KI Birkeland, ME Jørgensen, JP Wilding, ... Journal of the American College of Cardiology 71 (22), 2497-2506, 2018 | 119 | 2018 |
| Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review M Murton, D Goff-Leggett, A Bobrowska, JJ Garcia Sanchez, G James, ... Advances in therapy 38, 180-200, 2021 | 118 | 2021 |
| Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research PA Levin, H Nguyen, ET Wittbrodt, SC Kim Diabetes, metabolic syndrome and obesity: targets and therapy, 123-139, 2017 | 113 | 2017 |
| Potential Risk Factors Associated with Thrombocytop in a Surgical Intensive Care Unit MJ Cawley, ET Wittbrodt, EG Boyce, DJ Skaar Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19 (1 …, 1999 | 83 | 1999 |
| Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study S Kohsaka, CSP Lam, DJ Kim, MA Cavender, A Norhammar, ... The Lancet Diabetes & Endocrinology 8 (7), 606-615, 2020 | 80 | 2020 |
| Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R esults … M Kosiborod, KI Birkeland, MA Cavender, AZ Fu, JP Wilding, K Khunti, ... Diabetes, Obesity and Metabolism 20 (8), 1983-1987, 2018 | 76 | 2018 |
| Linezolid for the treatment of resistant gram-positive cocci KT Bain, ET Wittbrodt Annals of Pharmacotherapy 35 (5), 566-575, 2001 | 74 | 2001 |
| Daily interruption of continuous sedation ET Wittbrodt Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25 (5P2 …, 2005 | 52 | 2005 |
| Prevention of anaphylactoid reactions in high-risk patients receiving radiographic contrast media ET Wittbrodt, SA Spinler Annals of Pharmacotherapy 28 (2), 236-241, 1994 | 52 | 1994 |
| The challenges and opportunities associated with reimbursement for obesity pharmacotherapy in the USA C Baum, K Andino, E Wittbrodt, S Stewart, K Szymanski, R Turpin Pharmacoeconomics 33 (7), 643-653, 2015 | 48 | 2015 |
| Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population ET Wittbrodt, JM Eudicone, KF Bell, DM Enhoffer, K Latham, JB Green Am J Manag Care 24 (8 Suppl), S138-45, 2018 | 47 | 2018 |
| Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real … P McEwan, H Bennett, K Khunti, J Wilding, C Edmonds, M Thuresson, ... Diabetes, Obesity and Metabolism 22 (12), 2364-2374, 2020 | 39 | 2020 |
| Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: The ENhancing outcomes through Goal Assessment and Generating … JC Lauffenburger, R Ghazinouri, S Jan, S Makanji, CA Ferro, J Lewey, ... PloS one 14 (4), e0214754, 2019 | 39 | 2019 |
| Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes S Unni, E Wittbrodt, J Ma, M Schauerhamer, J Hurd, N Ruiz‐Negrón, ... Diabetes, Obesity and Metabolism 20 (2), 468-473, 2018 | 33 | 2018 |
| Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population ET Wittbrodt, JM Eudicone, KF Bell, DM Enhoffer, K Latham, JB Green Am J Manag Care 24 (8), S146-S155, 2018 | 31 | 2018 |
